MAPS Act
Sponsored By: Senator Gary Peters
Introduced
Summary
Map and reduce risks in the U.S. supply chain for essential medicines. This bill would create a federal Essential Medicines List (EML), require annual risk assessments of active pharmaceutical ingredients and finished drugs, and map supply-chain vulnerabilities using data analytics.
Show full summary
- Patients and families: Aims to prioritize medicines tied to chemical, biological, radiological, or nuclear threats and chronic conditions to help prevent shortages. HHS must update the EML at least every two years and deliver the first update within 180 days.
- Manufacturers and supply chains: Requires the Secretary to identify drugs that rely on foreign suppliers for more than 50 percent of production and to assess domestic manufacturing capacity and advanced manufacturing options. The bill directs creation of mitigation plans that may use authorities under the Defense Production Act.
- Defense and security: Requires the Department of Defense to report every 180 days on DoD-purchased drugs that contain APIs, excipients, or finished products sourced from China. The Secretary must send annual risk assessment reports to Congress with a public version due within one year.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Health Department Maintains Essential Medicines List
If enacted, the Health Department would create and keep an Essential Medicines List (EML). The list would include CBRN response drugs, drugs at high shortage risk, drugs critical for chronic patients, and drugs the Defense Department calls critical. HHS must finish the first update within 180 days of enactment. HHS must update the list at least every two years and publish it after each update.
Map and Reduce Drug Supply Risks
If enacted, HHS would map supply chains for drugs on the Essential Medicines List from starting materials to finished products. HHS and Defense would also do a risk assessment within 180 days and then yearly. The assessment must flag drugs or ingredients that rely on a high-risk foreign supplier for over 50 percent of production and must identify mitigation steps, including use of the Defense Production Act. HHS must report mapping progress not later than 18 months and describe data sharing, analytic methods, and cybersecurity protections. Information shared across agencies would be allowed while preserving trade secret and FOIA protections.
Defense Department Reports China Drug Links
If enacted, the Defense Department would report every 180 days on drugs it bought that used APIs, excipients, or finished products from China. The first report would be due within 180 days after enactment. These reports would publicly list DOD exposure to China-origin pharmaceutical inputs.
Sponsors & CoSponsors
Sponsor
Gary Peters
MI • D
Cosponsors
James Lankford
OK • R
Sponsored 5/15/2025
Joni Ernst
IA • R
Sponsored 5/15/2025
Tom Cotton
AR • R
Sponsored 5/15/2025
Timothy Kaine
VA • D
Sponsored 5/15/2025
Angus King
ME • I
Sponsored 5/15/2025
Rick Scott
FL • R
Sponsored 5/15/2025
Elissa Slotkin
MI • D
Sponsored 11/7/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in